Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0718 • ACR Convergence 2024
Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic
Laura Ramos Ortiz de Zarate¹, Aresio Plaza Lopez², Alejandro mARTINEZ rODADO³, Maria Machattou¹, Pablo Navarro Palomo⁴, maria alonso de francisco³, Carlota Navarro Joven³, Natalia de la Torre-Rubio⁴, Olga Rusinovich⁵, Carolina Merino⁶, Blanca García Magallón⁷, Jose Campos Esteban⁷, hildegarda Godoy Tundidor⁸, Mónica Fernández Castro⁹, JESUS SANZ SANZ⁴, Carmen Barbadillo Mateos⁷, Carlos Maria Isasi Zaragoza⁷, Andrea Liso Andrino⁷, Maria Concepcion Sanchez Fernandez³ and Jose Luis Andreu⁴, ¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ²Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Madrid, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁵Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ⁷Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, ⁸Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ⁹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is often linked to previous viral infections. Clinical evidence suggests SARS-CoV-2 virus may follow a similar pattern, with an…
Abstract Number: 0825 • ACR Convergence 2024
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study
Arielle Mendel¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Rosalie-Sélène Meunier⁹, Nataliya Milman¹⁰, Medha Soowamber¹¹, Jan Willem Cohen Tervaert¹², Elaine Yacyshyn⁴, Nader Khalidi¹³ and Christian Pagnoux¹⁴, ¹McGill University Health Centre, Montreal, QC, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Western University, Canada, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁹Hôpital Sacré-Coeur, Université de Montréal, Montreal, QC, Canada, ¹⁰the Ottawa Hospital, Ottawa, ON, Canada, ¹¹Mount Sinai Hospital, Woodbridge, ON, Canada, ¹²University of Alberta, Edmonton, Canada, ¹³McMaster University, Hamilton, ON, Canada, ¹⁴Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: To evaluate the effectiveness and safety of rituximab (RTX) biosimilars compared to the originator in Canadians with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…
Abstract Number: 1604 • ACR Convergence 2024
Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Peter Baudy², Donna Carstens², Benjamin North³, Mahvish Danka³, Stephanie Roy³, Hanna Marshall³ and Geoffrey Chupp⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Respiratory & Immunology US Medical, AstraZeneca, Wilmington, ³IQVIA, Philadelphia, ⁴School of Medicine, Yale University, New Haven
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis that can present indolently. This can lead to a delay in diagnosis and treatment. This study…
Abstract Number: 2478 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Christian Pagnoux¹, Antoine Neel², Sarah Bray³, Rachel E. Gurlin⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Internal Medicine, CHU Nantes, Nantes, France, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
Abstract Number: 2496 • ACR Convergence 2024
Clinical Features and Outcomes of Hydralazine-associated Vasculitis: A Case-Control Study
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba² and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: We aimed to investigate the relationship between hydralazine and any form of vasculitis (small, medium, or large vessel), to describe clinical features and outcomes…
Abstract Number: 0722 • ACR Convergence 2024
Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis
Andrea Hinojosa-Azaola¹, Marlon Sandino-Bermúdez², Ana Sarahí Mulia-Soto³, Juan M. Mejía-Vilet⁴ and Eduardo Martin Nares⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ⁴Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) encompass a group of systemic inflammatory diseases with multi-organ involvement. Relapses occur in 14-44% of patients within 18-36 months…
Abstract Number: 0826 • ACR Convergence 2024
Plasma Exchange for Severe Alveolar Hemorrhage in ANCA-Associated Vasculitis: Emulation of a Target Trial
Anne-Claire Sanna¹, Ségolène Gendreau², Cyrielle Desnos³, Dimitri Titeca-Beauport⁴, Jolan Malherbe⁵, Florian Reizine⁶, Kladoum Nassarmadji⁷, Louis Guillaume⁸, Alban Deroux⁹, Eddine Bendiab¹⁰, Jennifer Catano¹¹, Julien Campagne¹², Marc Pineton de Chambrun¹³, Valentin Coirier¹⁴, Clara Vigneron¹¹, Maxime SAMSON¹⁵, Antoine Neel¹⁶, Benoît Brilland¹⁷, Jean-Philippe Martellosio¹⁸, Maxim Desgrouas¹⁹, Olivier Simon²⁰, Perrine SMETS²¹, Romain Paule²², Stanislas Faguer²³, Stéphane Giorgiutti²⁴, Thylbert Deltombe²⁰, François Arrive¹⁸, Ingrid Masson²⁵, Thomas Quemeneur²⁶, Cécile Audrey Durel²⁷, Etienne de Montmollin¹¹, François Perrin²⁸, Herve Lobbes²⁹, Quentin Lajoye³⁰, Rafik Mesbah³¹, Rodéreau Outh³², Adeline Lacraz³³, Damien Contou³⁴, Fabien Parazols³⁵, Florian Garo³⁶, Grégoire Ducoux³⁷, Halil Yildiz³⁸, Isabelle Rey³⁹, Viviane Queyrel⁴⁰, Rita Eid¹¹, Robin Arcani⁴¹, Xavier Puéchal⁴², Raphael Porcher⁴³, Nicolas de Prost¹¹ and Benjamin Terrier⁴⁴, and French Vasculitis Study Group (FVSG); Groupe de Recherche en Réanimation Respiratoire du patient d'Onco-Hématologie (GrrrOH), ¹Cochin Hospital, Paris, France, ²Mondor Hospital, Paris, ³Tenon Hospital, Paris, France, ⁴CHU Amiens, Amiens, France, ⁵CHU Caen, Caen, France, ⁶CHU Vannes, Vannes, ⁷APHP, Paris, ⁸Hopital de Metz, Metz, France, ⁹Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ¹⁰CHU Montpellier, Montpellier, France, ¹¹APHP, Paris, France, ¹²Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, ¹³Sorbonne Université, Paris, France, ¹⁴CHU Rennes, Rennes, France, ¹⁵Dijon University Hospital, Dijon, France, ¹⁶Department of Internal Medicine, CHU Nantes, Nantes, France, ¹⁷CHU Angers, Angers, France, ¹⁸CHU Poitiers, Poitiers, France, ¹⁹CHU Orléans, Orleans, France, ²⁰CHU Réunion, Réunion, France, ²¹Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ²²Foch Hospital, Suresnes, France, ²³CHU Toulouse, Toulouse, France, ²⁴CHRU Strasbourg, Strasbourg, France, ²⁵CHU Saint Etienne, Saint Etienne, France, ²⁶CH Valenciennes, Valenciennes, France, ²⁷HCL, Lyon, France, ²⁸CH Saint Nazaire, Saint Nazaire, France, ²⁹CHU Clermont-Ferrand, Clermont-Ferrand, France, ³⁰CHU Bordeaux, Bordeaux, France, ³¹CH Boulogne, Boulogne, France, ³²CH, Perpignan, France,, Perpignan, France, ³³CH Bayonne, Bayonne, France, ³⁴CH Argenteuil, Argenteuil, France, ³⁵CH Perpignan, Perpignan, France, ³⁶CHU Nimes, Nimes, France, ³⁷CHU Lyon, Lyon, France, ³⁸Université de Louvain, Louvain, Belgium, ³⁹CH Annecy, Annecy, France, ⁴⁰CHU Nice, Nice, France, ⁴¹APHM, Marseille, France, ⁴²National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁴³Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ⁴⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Mortality is high in patients with diffuse alveolar hemorrhage (DAH) associated with ANCA-associated vasculitis (AAV). In the PEXIVAS study, plasma exchange (PLEX) did not have a…
Abstract Number: 1605 • ACR Convergence 2024
Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, David Jayne², Ulrich Specks³, Christian Pagnoux⁴, Parameswaran Nair⁵, Nader Khalidi⁵, Arnaud Bourdin⁶, Lena Börjesson Sjö⁷, Sofia Necander⁷, Anat Shavit⁸, Claire Walton⁹ and Michael Wechsler¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁶Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France, ⁷Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁰National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis. In the Phase 3, double-blind,…
Abstract Number: 2479 • ACR Convergence 2024
Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
Michael E Wechsler¹, Anna Kovalszki², Jared Silver³, Brian Stone⁴, Lior Seluk⁵, Lynn Huynh⁶, Wilson da Costa Junior⁶, Mingchen Ye⁶, Jeremiah Hwee⁷, Mei Sheng Duh⁶, William McCann⁴ and Amy G. Edgecomb⁸, ¹Department of Medicine, National Jewish Health, Denver, CO, ²Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³US Medical Affairs - Respiratory, GSK, Durham, ⁴Allergy Partners, Asheville, NC, ⁵Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, ⁶Analysis Group, Boston, MA, ⁷Value Evidence and Outcomes, GSK, Mississauga, Canada, ⁸US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
Abstract Number: 2497 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US
Muhammad Shamim¹, Mazen Allouni², Haseeb Chaudhary³, Ansaam Daoud⁴, Loai Dweik⁵, Hashim Syed⁶ and Omer Pamuk⁷, ¹University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ²Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ³Case Western Reserve University, Westlake, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵Cleveland Clinic Akron General Internal Medicine, Akron, OH, ⁶Case Western/ UH, Cleveland, ⁷University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem. There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…
Abstract Number: 0723 • ACR Convergence 2024
Sociodemographic Factors Associated with Clinic Non-attendance and Unscheduled Emergency Care Episodes in ANCA-associated Vasculitis
Warren RG James¹, Corri Black¹, Neil Basu², Mark A Little³ and Rosemary Hollick¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of Glasgow, Glasgow, Scotland, United Kingdom, ³Trinity College Dublin, Dublin, Ireland
Background/Purpose: Increasing evidence suggests that socioeconomic status drives differences in outcomes for people with rheumatic conditions. Individuals with complex, rare rheumatic conditions such as antineutrophil…
Abstract Number: 0828 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial
Peter Merkel¹, David Jayne², Ulrich Specks³, Christian Pagnoux⁴, Benjamin Terrier⁵, Bernhard Hellmich⁶, Sofia Necander⁷, Anat Shavit⁸, Claire Walton⁹ and Michael Wechsler¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁶Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁷Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁰National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by small- to medium-vessel vasculitis, asthma and eosinophilia. In the head-to-head MANDARA trial…
Abstract Number: 1606 • ACR Convergence 2024
Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, James M. Eudicone⁵, Amanda M. Moore⁶, Melissa Wilson⁷, Kinwei A. Chan⁶, Thomas Peer⁸ and Stephanie Y. Chen⁹, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁶TriNetX, Cambridge, MA, ⁷TriNetX, Durham, NC, ⁸TriNetX, Farmington, NY, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
Abstract Number: 2480 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
Robert Spiera¹, Robert Lebovics², Sarah Bray³, Rachel E. Gurlin⁴, David Jayne⁵ and Peter Merkel⁶, and ADVOCATE Study Group, ¹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²Hackensack Meridian University Health System, Hackensack, NJ, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…
Abstract Number: 2526 • ACR Convergence 2024
Development of the Hospital Emergency Advocacy & Treatment Kit (HEAT Kit) for Patients with Vasculitis
Sarah Jones¹, Pamela Squires² and Donna McArthur³, ¹Eosinophilic & Rare Disease Cooperative, Tucson, AZ, ²Eosinophilic & Rare Disease Cooperative, Tucson, ³Adjunct professor of nursing, Vanderbilt School of Nursing; Adjunct clinical professor, University of Arizona College of Nursing & Dept. of Neurology, Tucson, AZ
Background/Purpose: All forms of vasculitis are rare with patients frequently experiencing poor or extended care in the hospital and ED settings. The ERDC founder experienced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.